GeoVax Labs, Inc. (GOVX)
Stock Price:
$0.735 USD
0.015 (2.08%)
Updated Jul 31, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
10.17M |
| Revenue (ttm) |
1.53M |
| Net Income (ttm) |
-2.41M |
| Shares Out |
13.82M |
| EPS (ttm) |
-1.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 31, 2020 |
| Last Price |
$0.735 |
| Previous Close |
$0.720 |
| Change ($) |
0.015 |
| Change (%) |
2.08% |
| Day's Open |
0.730 |
| Day's Range |
0.700 - 0.790 |
| Day's Volume |
325,292 |
| 52-Week Range |
0.115 - 1.750 |
More Stats
| Market Cap |
10.17M |
| Enterprise Value |
9.63M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.82M |
| Float |
13.09M |
| EPS (basic) |
-7.47 |
| EPS (diluted) |
-1.84 |
| FCF / Share |
-0.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
1.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.66 |
| PB Ratio |
n/a |
| Revenue |
1.53M |
| Operating Income |
-3.62M |
| Net Income |
-2.41M |
| Free Cash Flow |
-1.62M |
| Net Cash |
538,702 |
| Net Cash / Share |
0.04 |
| Gross Margin |
-48.10% |
| Operating Margin |
-237.13% |
| Profit Margin |
n/a |
| FCF Margin |
-106.28% |
| ROA |
-217.33% |
| ROE |
n/a |
| ROIC |
182.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
10,000
Current: $0.735
High
10,000
Target: 10,000
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|
| Revenue | - | - | - | - | 0.88 | 2.42 | 2.66 | 4.90 | 5.19 | 3.67 |
| Revenue Growth | - | - | - | - | -63.48% | -9.02% | -45.77% | -5.5% | 41.36% | - |
| Gross Profit | - | - | - | - | 0.88 | 2.42 | 2.66 | 4.90 | 5.19 | 3.67 |
| Operating Income | -3.53 | -3.25 | -4.10 | -3.12 | -2.74 | -2.29 | -2.14 | -2.35 | -2.77 | -3.32 |
| Net Income | -2.56 | -2.17 | -3.27 | -2.69 | -2.73 | -2.28 | -2.14 | -2.35 | -2.75 | -3.28 |
| Shares Outstanding | 0.33 | 0.14 | 0.08 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| Earnings Per Share | -10.00 | -15.00 | -40.00 | -40.00 | -50.00 | -55.00 | -60.00 | -75.00 | -90.00 | -110.00 |
| Operating Cash Flow | -1.54 | -1.69 | -1.95 | -2.71 | -2.25 | -1.69 | -2.44 | -0.30 | -2.44 | -1.43 |
| Capital Expenditures | - | - | - | -0.02 | -0.04 | -0.09 | - | -0.01 | - | -0.27 |
| Free Cash Flow | -1.54 | -1.69 | -1.95 | -2.72 | -2.29 | -1.78 | -2.44 | -0.32 | -2.44 | -1.70 |
| Cash & Equivalents | 0.27 | 0.32 | 0.47 | 1.06 | 1.10 | 2.51 | 1.04 | 1.17 | 1.08 | 3.52 |
| Total Debt | 0.30 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | -0.03 | 0.32 | 0.47 | 1.06 | 1.10 | 2.51 | 1.04 | 1.17 | 1.08 | 3.52 |
| Assets | 0.64 | 0.49 | 0.61 | 1.33 | 1.33 | 2.84 | 1.48 | 1.65 | 2.36 | 4.32 |
| Liabilities | 1.66 | 0.81 | 0.37 | 0.13 | 0.19 | 0.31 | 0.33 | 0.94 | 0.52 | 0.57 |
| Book Value | -1.02 | -0.32 | 0.24 | 1.20 | 1.15 | 2.53 | 1.15 | 0.70 | 1.84 | 3.74 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
GeoVax Labs, Inc. |
| Country |
United States |
| Employees |
6 |
| CEO |
David A. Dodd |
Stock Information
| Ticker Symbol |
GOVX |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: GOVX |
Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.